Biosimilars could improve health system sustainability in Slovakia; however, of the 54 biosimilars approved by the European Medicines Agency as of August 2019, fewer than half are available in Slovakia
Of the 54 biosimilars approved by the European Medicines Agency (EMA) as of August 2019, fewer than half (24) are available in Slovakia, but if the remaining 30 biosimilars were available the nation’s health fund could save €35 million to €50 million (approximately $41 million to $59 million) per year, according to a new study.
Biosimilar Availability in Slovakia
The authors first compared biosimilar use among Visegrád Group (V4) countries: the Czech Republic, Hungary, Poland, and Slovakia. Of the 54 biosimilars approved by the EMA, 29 were available in the Czech Republic, 28 in Poland, 27 in Hungary, and only 24 in Slovakia.
Looking at biosimilar availability over time, the authors noted that 6 biosimilars became available in Slovakia between 2013 and 2015, but no new biosimilar drugs were added to the reimbursement list until the second half of 2018. Since then, the Ministry of Health added 15 more biosimilar drugs. Some of these biosimilars were added following expiration of patents on the reference drugs, and others were able to enter the market once Slovakia’s Ministry of Health reduced their compulsory price discount for biosimilars, which took effect in January 2019.
As of January 2019, Slovakia’s Ministry of Health requires that the first biosimilar marketed for a particular active substance to cost 25% less than the reference product (down from 30%). The second marketed biosimilar must cost 30% less than the reference drug, and the third must cost 35% less.
The authors also noted that biosimilar drugs containing the active substances somatotropin, enoxaparin, and insulin lispro are not yet available in Slovakia.
Market Share
In 2018, filgrastim biosimilars had the greatest market share of biosimilars in Slovakia at 99.93%, followed by erythropoietin biosimilars at 75.44%, insulin glargine biosimilars at 36.29%, infliximab biosimilars at 25.07%, and follitropin alfa biosimilars at 21.11%. Rituximab and trastuzumab biosimilars have been introduced since 2018 but have so far gained paltry market share at 2.31% and 0.07%, respectively.
Cost Savings
The authors argued biosimilars could improve health system sustainability in Slovakia, remarking that reference biologics are often too expensive for Central and Eastern European countries, since “the launch price of high-cost biologic medicines is set according to the highest acceptable price by payers in large and high-income countries with the greatest market potential. These prices are frequently not acceptable in lower income countries.”
The researchers calculated potential cost savings using 2018 price data, assumed no increase in the use of biosimilars, and estimated a 25% to 35% lower price compared with reference products, consistent with Slovak Ministry of Health requirements.
Based on data provided by drug distributors to the State Institute for Drug Control, the authors calculated cost savings of between €35.44 million and €49.62 million (approximately $41.60 million to $58.25 million) per year if more biosimilars were more widely available in Slovakia. They validated their calculations using data from payers provided to the National Health Information Center, which resulted in estimated cost savings of €26.65 million to €37.32 million (approximately $31.28 million to $43.81 million) per year.
Appropriate Regulation of Pricing
The authors acknowledged that cost savings are limited by the complexity and expense of the manufacturing process for biosimilars; however, they wrote that “absolute cost savings could still be significant because of the high prices and volumes of the reference medicines.”
The authors also cautioned that Slovakia’s mandatory price discounts and strict rules for international price referencing undermine the overall strategy of trying to lower biosimilar prices by discouraging manufacturers from marketing their products in the country. Most European Union member states, they wrote, regulate drug prices similarly based on referrals from other member states, which may motivate manufacturers “to maintain higher list prices even for less affluent countries, so that list prices do not drop across the European market.”
The authors argued, “It is therefore important for buyers to set appropriate price reduction rules. From an economic point of view, price regulation is needed unless fair competition generates a market price.”
They also pointed out the ultimate goal is the potential benefit to the health of the society, saying “the role of biosimilars is not only about cost-saving potential but improving patient access to needed biological pharmacotherapy and ultimately to improve health status of the society.”
Maximizing the Social Benefit of Biosimilars
The authors concluded with a list of recommended policy practices to maximize the social benefit of biosimilars. These included:
Reference
Tesar T, Golias P, Kobliskova Z, Wawruch M, Kawalec P, Inotai A. Potential cost-savings from the use of the biosimilars in Slovakia. Front Public Health. Published online August 21, 2020. doi:10.3389/fpubh.2020.00431
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.